Immune Modulators and IVF
| Status: | Recruiting |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 44 |
| Updated: | 11/16/2018 |
| Start Date: | July 2015 |
| End Date: | December 2019 |
| Contact: | Mitasha C Joseph-Sohan, BSN, MPA |
| Email: | mij2008@med.cornell.edu |
| Phone: | 646-962-3382 |
Immune Modulators in Women Undergoing IVF----a Prospective Study
Exploring the immune mediators of early pregnancy prospectively may help to identify new
early interventions that will increase the likelihood of success and help women make informed
decisions regarding their pregnancies.
early interventions that will increase the likelihood of success and help women make informed
decisions regarding their pregnancies.
Sera will be obtained from 500 women undergoing IVF at five time periods: cycle Day 2, post
HCG, Day 24, Day 28, and/or Day 35.Aliquots of sera will be tested by commercial ELISA kits
for concentrations of immune modulators suggestive to be predictive of IVF outcome, such as
cytokines (interleukins, tumor necrosis factor, and interferon), neurotrophins (BDNF),
protease inhibitors (HE4) and insulin-like growth factors (IGF-1, IGF-2, IGFBP). The results
will be correlated with IVF outcomes.
HCG, Day 24, Day 28, and/or Day 35.Aliquots of sera will be tested by commercial ELISA kits
for concentrations of immune modulators suggestive to be predictive of IVF outcome, such as
cytokines (interleukins, tumor necrosis factor, and interferon), neurotrophins (BDNF),
protease inhibitors (HE4) and insulin-like growth factors (IGF-1, IGF-2, IGFBP). The results
will be correlated with IVF outcomes.
Inclusion Criteria:
- All fresh transfers
Exclusion Criteria:
- PGD
We found this trial at
1
site
New York, New York 10021
Principal Investigator: Steven Spandorfer, MD
Phone: 646-962-3382
Click here to add this to my saved trials
